Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13
In the Phase 2 trial protocol, participants began at a low starting dose commonly 2 mg once weekly before progressing through incremental increases over several months, with target maintenance doses ranging from 8 mg to 12 mg weekly depending on tolerability and clinical response
Improved glycemic control : Significantly reduces blood glucose levels in people with type 2 diabetes
The most common side effects of tirzepatide are gastrointestinal: Nausea: Reported by 12-33% of participants depending on dose (most common early in treatment) Diarrhea: 12-21% of participants Constipation: 6-11% of participants Vomiting: 5-13% of participants Decreased appetite: Expected therapeutic effect but can be uncomfortable These side effects are typically most intense during the first few weeks at each new dose level and tend to improve as the body adjusts
AOD-9604 Timeline & What to Monitor Setting realistic expectations is the most useful thing this section can do, because the published evidence is much more modest than typical clinic marketing
It should start working within an hour sometimes sooner
